SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer s Disease (AD): A Phase 1b/2a, Multi-center, Randomized, Double-Blind, Placebo-Controlled Safety and Biomarker Study of Pepinemab Anti-SEMA4D Antibody in early-AD

10283VX15/2503-11Open (affiliates only)SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer s Disease (AD): A Phase 1b/2a, Multi-center, Randomized, Double-Blind, Placebo-Controlled Safety and Biomarker Study of Pepinemab Anti-SEMA4D Antibody in early-ADNCT04381468IndustrialAdultTreatmentOtherTurner, RaymondGeorgetown University Medical Center; Lombardi Comprehensive Cancer CenterGUMC Neurology2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>